about
Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: the Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives.Mechanism of inhibition of GluA2 AMPA receptor channel opening by 2,3-benzodiazepine derivatives: functional consequences of replacing a 7,8-methylenedioxy with a 7,8-ethylenedioxy moietyPeptide-based proteasome inhibitors in anticancer drug design.Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors.Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3.Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II.Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors.Synthesis and molecular modeling studies of derivatives of a highly potent peptidomimetic vinyl ester as falcipain-2 inhibitors.Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro.Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain.Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.Novel potent AMPA/kainate receptor antagonists: synthesis and anticonvulsant activity of a series of 2-[(4-alkylsemicarbazono)-(4-amino-phenyl)methyl]-4,5-methylenedioxyphenylacetic acid alkyl esters.Synthesis and antitumor activity of 1,3-benzodioxole derivatives.Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists.5-phenyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-8(7H)-one.Design of 1-substituted 2-arylmethyl-4,5-methylenedioxybenzene derivatives as antiseizure agents.New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists.Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist.Mechanism of falcipain-2 inhibition by α,β-unsaturated benzo[1,4]diazepin-2-one methyl ester.Synthesis of C3/C1-Substituted Tetrahydroisoquinolines.Identification of a new series of amides as non-covalent proteasome inhibitors.Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors.Discovery of benzimidazole-based L. mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis.1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agentsA SIMPLE AND EFFICIENT SYNTHESIS OF GYKI 52466 AND GYKI 52895Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-onesSynthesis and Anticonvulsant Activity of Novel and Potent 2,3-Benzodiazepine AMPA/Kainate Receptor AntagonistsDevelopment of peptidomimetic boronates as proteasome inhibitorsSelected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activitiesDevelopment of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome InhibitorsPeptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitorsNovel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial AgentsSynthesis, Chiral Resolution and Pharmacological Evaluation of a 2,3-Benzodiazepine-Derived Noncompetitive AMPA Receptor AntagonistEnantioselective recognition of 2,3-benzodiazepin-4-one derivatives with anticonvulsant activity on several polysaccharide chiral stationary phasesEnantioseparation, absolute configuration determination, and anticonvulsant activity of (±)-1-(4-aminophenyl)-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-one
P50
Q34068562-2D19E033-7155-4411-A61D-595B8BF30FB7Q34150442-0A9CD624-747F-4A07-9C9E-801AAB3C057FQ38192572-EE5E1694-4512-4B4B-BB58-C9D9CE3942C5Q38982918-7A49D668-68EB-4AB9-B6F8-5A9A9BC3AB3BQ38988876-7395DF84-DB98-4ED8-9658-B29BB89CA524Q39871302-45A10052-DADF-4105-8E49-C3125F212B17Q40482934-0A0C5C6F-EEEA-4D7D-8B6F-4CEF4EA2D74AQ40650307-DAD86BE1-B712-42DA-A48F-85EE94589558Q42167513-CECEBCF8-97C5-497A-B10B-DB6ED90EEC2BQ42717133-2452846F-A4C9-4124-A052-A433A5257ED9Q42724002-DD3F6AD4-0220-46BA-BA89-A91E7D966D7FQ42991352-8B6611B5-8DE9-4700-9E8A-99F5E818D870Q43077558-5E88E3DA-051B-4CE5-8F6A-16E627F65D74Q43285388-3AEF2464-76E6-4C9B-922A-F7FAF624120BQ44142641-AB1D9175-1F97-4AC4-830E-DD5E920CC5F5Q44208556-930CCFD9-F696-4EC0-ABCD-F3EE4D1FB0BFQ44301650-6129A034-EFAF-4CCD-9504-D6434B0F5B04Q44414666-9EE09045-D4D6-4384-830E-6B640C8896B5Q44928780-05553DD9-0DC0-4117-BB3D-1BDCBE1AD523Q46745419-4CCB9AEC-7344-4655-A93F-8BED1C87EB28Q46783287-107B4A9C-DCCE-4A0F-98A7-622AB54C5BB7Q46787191-1659F2A7-FF11-4372-BE52-FF99336AE3C0Q46899017-6BAA7B3E-B4BB-4F45-840E-75F5FE27384BQ50503846-DBABB2BD-59E3-4EA3-9DDC-2278B45B62AFQ50944497-915CDA41-F446-467F-BF8C-6CD4CC08AA04Q51751951-C553D377-5ABC-44D4-BBAC-29608AAAE61BQ51981176-365588F2-C099-4FB0-AA15-1FB0C4DD3A03Q53687544-9D1FF9A4-C372-4875-942E-024111D0E10DQ58853573-BA339A5D-E284-4105-8CED-E90DC5EC407AQ58853574-30D47040-3813-4F82-8015-8D1E3604FE1CQ58853576-C9349464-2F83-4410-878D-671CFC0052D1Q58853580-4D2C4585-BF1A-49DF-887C-F62B8C51206EQ58855688-229F2994-653B-49E6-92E6-3DFF89CB637BQ58856043-499A017F-70DB-41C6-BD36-56577B1D8E9CQ58862067-5B2ECB40-F046-4637-B57C-98EC0D47CFFBQ58862073-E6D3D738-50B1-465F-9EA4-6BC6A97EB3C1Q58862082-1D7F0ABB-3B63-415D-B819-6C01380B6F8BQ58862988-5752707E-6F7B-41F6-994B-04D9D49801DAQ58862991-D2593370-8E73-47CD-9DE0-4FDE5670CE87Q58862993-EE8B38B1-46A5-4CB2-AD46-30BC76AC7882
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Micale
@ast
Nicola Micale
@en
Nicola Micale
@es
Nicola Micale
@nl
type
label
Nicola Micale
@ast
Nicola Micale
@en
Nicola Micale
@es
Nicola Micale
@nl
prefLabel
Nicola Micale
@ast
Nicola Micale
@en
Nicola Micale
@es
Nicola Micale
@nl
P106
P1153
6602672514
P21
P31
P496
0000-0002-9294-6033